Histamine H3 receptors and their role in basal ganglia physiology and pathophysiology

Signal Transduction

Volumn 7, Issue 5-6, 2007, Pages 364-371

  Arias Montaño, José Antonio ^a,b  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b Cinvestav   (Mexico)

Author keywords

Basal ganglia; Dopamine receptors; Histamine; Histamine H3 receptors; Parkinson's disease

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINOBUTYRIC ACID; ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; CALCIUM CHANNEL; CIPROXIFAN; CLOBENPROPIT; GLUTAMIC ACID; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE A2; POTASSIUM CHANNEL; PROTEIN KINASE B; THIOPERAMIDE;

BASAL GANGLION; BRAIN FUNCTION; CHEMICAL STRUCTURE; DRUG ACTIVITY; ENZYME ACTIVATION; HORMONE RELEASE; HUMAN; ION EXCHANGE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 38749083047     PISSN: 16154053     EISSN: 16154061     Source Type: Journal    
DOI: 10.1002/sita.200700139     Document Type: Review

References (47)

1. Haas, H., Panula, P. (2003) The role of histamine and the tuberomamillary nucleus in the nervous system. Nature Rev. Neurosci. 4: 121-130.
2. 3 receptor drugs. Nature Rev. Drug Discov. 4: 107-121.
3. 3 receptors regulate acetylcholine release from the guinea pig ileum myenteric plexus. Life Sci. 48: 63-68.
4. 3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc. Natl. Acad. Sci. U.S.A. 99: 501-506.
5. 3 receptor and its gene transcripts in rat brain. Neuroscience 114: 173-193.
6. 3) of histamine receptor. Nature 302: 832-837.
7. 3-receptors. Neuroscience 23: 149-157.
8. 3-receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 337: 588-590.
9. 3 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 340: 633-638.
10. 3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo. Eur. J. Pharmacol. 174: 49-55.
11. 3- selective ligands. Br. J. Pharmacol. 101: 621-624.
12. 3-receptors. J. Neural Transm. 93: 1-10.
13. Doreulee, N., Yanovsky, Y., Flagmeyer, I., Stevens, D.R., Haas, H.L., Brown, R.E. (2001) Histamine H3 receptors depress synaptic transmission in the corticostriatal pathway. Neuropharmacology 40: 106-113.
14. 3 receptor activation inhibits glutamate release from rat striatal synaptosomes. Neuropharmacology 41: 928-934.
15. 3H]GABA release from depolarisation-stimulated slices of rat substantia nigra pars reticulata. Neuroscience 80: 241-249.
16. 3H]-γ-aminobutyric acid in rat striatum. Br. J. Pharmacol. 133: 165-171.
17. 3 receptor. Mol. Pharmacol. 55: 1101-1107.
18. 3 receptor. Biochem. Pharmacol. 73: 1195-1204.
19. 3 isoform confers pharmacological differences and constitutive activity. J. Pharmacol. Exp. Ther. 323: 888-898.
20. 3-receptor isoforms. Inflamm. Res. 53: 509-516.
21. 3 receptor isoforms. Society for Neuroscience Abstracts, 878.1/G21.
22. 3 receptor that act as dominant-negative isoforms. Mol. Pharmacol. 69: 1194-1206.
23. 3 receptor. Trends Pharmacol. Sci. 28: 350-357.
24. 3 receptors regulates histamine neurons in brain. Nature 408: 860-864.
25. 3 receptors. Br. J. Pharmacol. 135: 383-392.
26. Takeshita, Y., Watanabe, T., Sakata, T., Munakata, M., Ishibashi, H., Akaike, N. (1998) Histamine modulates high-voltage-activated calcium channels in neurons dissociated from the rat tuberomammillary nucleus. Neuroscience 87: 797-805.
27. + exchange: a novel protective mechanism in myocardial ischemia. Proc. Natl. Acad. Sci. U.S.A. 98: 2855-2859.
28. 3 receptor couples to GIRK channels in Xenopus oocytes. Eur. J. Pharmacol. 567: 206-210.
29. Marinissen, M.J., Gutkind, J.S. (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci. 22: 368-376.
30. 3 receptor. J. Neurochem. 103: 248-258.
31. 3 receptors in rat brain areas. Neuroscience 52: 169-189.
32. Gerfen, C.R., Wilson, C.J. (1996) The basal ganglia. In Integrated Systems of the CNS, Part III (Handbook of Chemical Neuroanatomy, Vol. 12). Eds.: Björklund, A., Hökfelt, T., Swanson, L. Elsevier, Amsterdam (The Netherlands), pp. 369-466.
33. 1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat. Neurosci. Lett. 116: 136-140.
34. Ryu, J.H., Yanai, K., Iwata, R., Ido, T., Watanabe, T. (1994) Heterogenous distribution of histamine H3, dopamine D1 and D2 receptors in rat brain. NeuroReport 5: 621-624.
35. 1 receptor facilitation of depolarisation-induced release of γ-aminobutyric acid (GABA) in rat striatum is mediated predominantly via P/Ojtype calcium channels. Synapse 61: 310-319.
36. 3 receptors regulate glutamate, but not GABA release in rat thalamus. Neuropharmacology 52: 527-535.
37. 3-receptor activation inhibits dopamine synthesis in rat striatum. NeuroReport 17: 163-166.
38. Gainetdinov, R.R., Premont, R.T., Bohn, L.M., Lefkowitz, R.J., Caron, M.G. (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci. 27: 107-144.
39. 3 receptors in rat striatal slices. Synapse 60: 165-171.
40. 3 agonist immepip and systemic apomorphine elicit ipsilateral turning behaviour in naive rats, but reduce contralateral turning in hemiparkinsonian rats. Behav. Brain Res. 154: 409-415.
41. 1 receptor-induced cAMP formation in rat striatum. Neurosci. Lett. 364: 179-184.
42. Anichtchik, O.V., Rinne, J.O., Kalimo, H., Panula, P. (2000) An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp. Neurol. 163: 20-30.
43. Rinne, J.O., Anichtchik, O.V., Eriksson, K.S., Kaslin, J., Tuomisto, L., Kalimo, H., Roytta, M., Panula, P. (2002) Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J. Neurochem. 81: 954-960.
44. Anichtchik, O.V., Peitsaro, N., Rinne, J.O., Kalimo, H., Panula, P. (2001) Distribution and modulation of histamine H3 receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol. Dis. 8: 707-717.
45. Schapira, A.H., Bezard, E., Brotchie, J., Calon, F., Collingridge, G.L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Le Novere, N., Obeso, J.A., Schwarzschild, M.A., Spampinato, U., Davidai, G. (2006) Novel pharmacological targets for the treatment of Parkinson's disease. Nature Rev. Drug Discov. 5: 845-854.
46. Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J.A., Hervé, D., Greengard, P., Fisone, G. (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA induced dyskinesia. J. Neurosci. 27: 6995-7005.
47. Gomez-Ramírez, J., Johnston, T.H., Visanji, N.P., Fox, S.H., Brotchie, J.M. (2006) Histamine H3 receptor agonists reduce L-DOPA-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disord. 21: 839-846.